GE Healthcare agreed to pay $30 million to resolve allegations that it improperly marketed Myoview, a diagnostic drug used in cardiology tests, by encouraging physicians to dilute the drug in order to use the product on more patients than intended.  In addition to going against the FDA’s drug label directions and potentially causing false positives in patient tests, the alleged practice allowed physicians to bill Medicare multiple times for the product.

The whistleblower, an individual who sold a competitor drug, will receive $5.1 million from the settlement.

Read the entire article, “Pharmaceutical firm to pay $30M settlement in false claims suit”